Intuitive Surgical, Inc. $ISRG Position Lessened by Philadelphia Trust Co.

Philadelphia Trust Co. lessened its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 17,165 shares of the medical equipment provider’s stock after selling 1,231 shares during the period. Philadelphia Trust Co.’s holdings in Intuitive Surgical were worth $6,980,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Fairscale Capital LLC raised its position in Intuitive Surgical by 3.5% in the third quarter. Fairscale Capital LLC now owns 645 shares of the medical equipment provider’s stock worth $279,000 after acquiring an additional 22 shares in the last quarter. Beaumont Financial Advisors LLC lifted its holdings in Intuitive Surgical by 3.8% in the 3rd quarter. Beaumont Financial Advisors LLC now owns 627 shares of the medical equipment provider’s stock valued at $255,000 after acquiring an additional 23 shares during the last quarter. Hughes Financial Services LLC boosted its position in shares of Intuitive Surgical by 40.7% during the 3rd quarter. Hughes Financial Services LLC now owns 83 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 24 shares in the last quarter. W.G. Shaheen & Associates DBA Whitney & Co boosted its position in shares of Intuitive Surgical by 1.0% during the 1st quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 2,542 shares of the medical equipment provider’s stock valued at $1,172,000 after purchasing an additional 25 shares in the last quarter. Finally, Blue Fin Capital Inc. boosted its position in shares of Intuitive Surgical by 0.5% during the 1st quarter. Blue Fin Capital Inc. now owns 4,794 shares of the medical equipment provider’s stock valued at $2,210,000 after purchasing an additional 25 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 2.3%

NASDAQ ISRG opened at $450.04 on Wednesday. The stock’s 50-day moving average price is $413.15 and its two-hundred day moving average price is $431.20. The company has a market cap of $156.00 billion, a PE ratio of 54.42, a PEG ratio of 3.17 and a beta of 1.45. Intuitive Surgical, Inc. has a 1 year low of $328.57 and a 1 year high of $603.88.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. Intuitive Surgical had a net margin of 25.54% and a return on equity of 18.17%. The company had revenue of $3.05 billion during the quarter, compared to analyst estimates of $2.91 billion. During the same period in the prior year, the firm earned $2.40 earnings per share. The business’s quarterly revenue was up 21.7% on a year-over-year basis. Research analysts forecast that Intuitive Surgical, Inc. will post 9.37 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on ISRG. Wall Street Zen upgraded shares of Intuitive Surgical from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. UBS Group reissued a “buy” rating on shares of Intuitive Surgical in a research note on Tuesday, October 13th. Wells Fargo & Company restated an “overweight” rating and set a $486.00 target price (down from $487.00) on shares of Intuitive Surgical in a report on Wednesday, October 21st. TD Cowen restated a “buy” rating and issued a $485.00 price target on shares of Intuitive Surgical in a research report on Monday, October 19th. Finally, BNP Paribas Exane raised Intuitive Surgical to an “outperform” rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $493.54.

Insider Buying and Selling at Intuitive Surgical

In other Intuitive Surgical news, EVP Mark Brosius sold 61 shares of the company’s stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $441.60, for a total transaction of $26,937.60. Following the completion of the sale, the executive vice president owned 581 shares of the company’s stock, valued at $256,569.60. This represents a 9.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Craig H. Barratt sold 1,150 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $460.00, for a total value of $529,000.00. Following the transaction, the director owned 1,150 shares in the company, valued at approximately $529,000. This trade represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 39,056 shares of company stock valued at $17,585,864 over the last three months. 0.60% of the stock is owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.